Rapamycin inhibits cell proliferation in type i and type II endometrial carcinomas: A search for biomarkers of sensitivity to treatment

Gynecologic Oncology

Volumn 119, Issue 3, 2010, Pages 579-585

  Bae Jump, Victoria L ^a   Zhou, Chunxiao ^a,b   Boggess, John F ^a,b   Whang, Young E ^a,b   Barroilhet, Lisa ^c   Gehrig, Paola A ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Akt; Endometrial carcinoma; hTERT; mTOR pathway; PTEN; Rapamycin

Indexed keywords

BIOLOGICAL MARKER; INITIATION FACTOR 4E BINDING PROTEIN 1; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; CANCER RESISTANCE; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; DRUG SENSITIVITY; ENDOMETRIUM CARCINOMA; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; TELOMERE; TISSUE CULTURE; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, ENDOMETRIOID; CELL GROWTH PROCESSES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM STAGING; RNA, MESSENGER; SIROLIMUS; TELOMERASE; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 78149357205     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.08.025     Document Type: Article

References (38)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 4 2009 225 249
2. J.V. Bokhman Two pathogenetic types of endometrial carcinoma Gynecol Oncol 15 1 1983 10 17
3. M. Abal, J. Planaguma, and A. Gil-Moreno Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors Histol Histopathol 21 2 2006 197 204
4. J.L. Hecht, and G.L. Mutter Molecular and pathologic aspects of endometrial carcinogenesis J Clin Oncol 24 29 2006 4783 4791
5. S.F. Lax Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification Virchows Arch 444 3 2004 213 223
6. R.A. Ambros, M.E. Sherman, C.M. Zahn, P. Bitterman, and R.J. Kurman Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation Hum Pathol 26 11 1995 1260 1267
7. Gehrig PA, Bae-Jump VL. Promising novel therapies for the treatment of endometrial cancer. Gynecol Oncol 2010;116(2):187-94.
8. G.L. Mutter, M.C. Lin, and J.T. Fitzgerald Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers J Natl Cancer Inst 92 11 2000 924 930
9. L.C. Cantley, and B.G. Neel New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway Proc Natl Acad Sci U S A 96 8 1999 4240 4245
10. N. Pullen, and G. Thomas The modular phosphorylation and activation of p70s6k FEBS Lett 410 1 1997 78 82
11. N. Sonenberg, and A.C. Gingras The mRNA 5′ cap-binding protein eIF4E and control of cell growth Curr Opin Cell Biol 10 2 1998 268 275
12. C. Zhou, P.A. Gehrig, Y.E. Whang, and J.F. Boggess Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells Mol Cancer Ther 2 8 2003 789 795
13. I. Bieche, C. Nogues, and V. Paradis Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay Clin Cancer Res 6 2 2000 452 459
14. H.B. Jefferies, S. Fumagalli, P.B. Dennis, C. Reinhard, R.B. Pearson, and G. Thomas Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k EMBO J 16 12 1997 3693 3704
15. A.C. Gingras, B. Raught, and N. Sonenberg Regulation of translation initiation by FRAP/mTOR Genes Dev 15 7 2001 807 826
16. A. Pause, N. Methot, Y. Svitkin, W.C. Merrick, and N. Sonenberg Dominant negative mutants of mammalian translation initiation factor eIF-4A define a critical role for eIF-4F in cap-dependent and cap-independent initiation of translation EMBO J 13 5 1994 1205 1215
17. N. Bansal, V. Yendluri, and R.M. Wenham The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies Cancer Control 16 1 2009 8 13
18. K. Oda, D. Stokoe, Y. Taketani, and F. McCormick High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma Cancer Res 65 23 2005 10669 10673
19. K. Podsypanina, R.T. Lee, and C. Politis An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice Proc Natl Acad Sci U S A 98 18 2001 10320 10325
20. Y. Shi, J. Gera, and L. Hu Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779 Cancer Res 62 17 2002 5027 5034
21. V. Grunwald, L. DeGraffenried, D. Russel, W.E. Friedrichs, R.B. Ray, and M. Hidalgo Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells Cancer Res 62 21 2002 6141 6145
22. M.S. Neshat, I.K. Mellinghoff, and C. Tran Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc Natl Acad Sci U S A 98 18 2001 10314 10319
23. W.C. Noh, W.H. Mondesire, and J. Peng Determinants of rapamycin sensitivity in breast cancer cells Clin Cancer Res 10 3 2004 1013 1023
24. V.L. Bae-Jump, C. Zhou, P.A. Gehrig, Y.E. Whang, and J.F. Boggess Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest Gynecol Oncol 100 3 2006 487 494
25. K. Yu, L. Toral-Barza, and C. Discafani mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer Endocr Relat Cancer 8 3 2001 249 258
26. L. Yang, M.J. Clarke, and B.L. Carlson PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel Clin Cancer Res 14 12 2008 3993 4001
27. M. Breuleux, M. Klopfenstein, and C. Stephan Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition Mol Cancer Ther 8 4 2009 742 753
28. A. Boulay, S. Zumstein-Mecker, and C. Stephan Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells Cancer Res 64 1 2004 252 261
29. J.M. Peralba, L. DeGraffenried, and W. Friedrichs Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients Clin Cancer Res 9 8 2003 2887 2892
30. J. Tabernero, F. Rojo, and E. Calvo Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors J Clin Oncol 26 10 2008 1603 1610
31. L. Dudkin, M.B. Dilling, and P.J. Cheshire Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition Clin Cancer Res 7 6 2001 1758 1764
32. Houghton PJ. Everolimus. Clin Cancer Res 2010;16(5):1368-72.
33. S.A. Stewart, and R.A. Weinberg Telomerase and human tumorigenesis Semin Cancer Biol 10 6 2000 399 406
34. Y. Yokoyama, Y. Takahashi, A. Shinohara, Z. Lian, and T. Tamaya Telomerase activity in the female reproductive tract and neoplasms Gynecol Oncol 68 2 1998 145 149
35. P.S. Zheng, T. Iwasaka, and F. Yamasaki Telomerase activity in gynecologic tumors Gynecol Oncol 64 1 1997 171 175
36. X. Zhu, R. Kumar, and M. Mandal Cell cycle-dependent modulation of telomerase activity in tumor cells Proc Natl Acad Sci U S A 93 12 1996 6091 6095
37. S.E. Holt, D.L. Aisner, J.W. Shay, and W.E. Wright Lack of cell cycle regulation of telomerase activity in human cells Proc Natl Acad Sci U S A 94 20 1997 10687 10692
38. U. Svenson, and G. Roos Telomere length as a biological marker in malignancy Biochim Biophys Acta 1792 4 2009 317 323